Ma muli o ka ulu ʻana o ka mitral valve regurgitation a me ka mitral valve stenosis ma ka honua holoʻokoʻa, e 2026, ʻo ka maʻi puʻuwai mitral valve i ka mākeke transcatheter heart valve e hoʻokō i kahi ulu nui o 23.1%.
PR Newswire-PR Newswire Selbyville, Delaware, USA, Ianuali 18, 2021-E like me ka hōʻike hou loa "Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral) Valve repair and replacement, transcatheter pulmonary valve replacement), ʻoki nā ala (transfemoral approach, transapical approach), noi (aortic valve heart disease, mitral valve heart disease, pulmonary valve heart disease), hoʻohana hope (hale maʻi, cath lab), ka nānā ʻāina, nā kumu kumukūʻai, ka māhele mākeke hoʻokūkū a me ka wānana 2026 "na: Global Market Insights, Inc, 2026, ʻoi aku ka nui o ka mākeke o ka transcatheter heart valve replacement surgery ma luna o 19.5 biliona. Dala.
ʻO nā papahana hoihoi maikaʻi ma ʻAmelika ʻAmelika a me ʻEulopa e hāpai i ka ulu ʻana o ka mākeke. ʻO ka Medicare National Coverage Decision he kulekele i hoʻolaha ʻia e Medicare a me nā Centers for Medicaid Services (CMS) e ʻae i kēia mau puʻuwai puʻuwai e uhi ʻia e ka uhi i kākoʻo ʻia e nā hōʻike ma United States. I ka makahiki 2019, ua hoʻonui ʻo CMS i ke kulekele hoʻihoʻi Medicare no nā kīwaha aortic transcatheter. Polokalamu Hoʻololi (TAVR). Ke hana ʻia ke ʻokiʻoki e like me nā ʻōlelo aʻoaʻo i ʻāpono ʻia e FDA, e hoʻomau ʻia ke kulekele uhi aupuni hou e uhi iā TAVR me ka Evidence Development (CED). Eia kekahi, hāʻawi ʻo Belgium a me Farani i nā uku no kekahi mau hōʻailona, aʻo nā ʻāina ʻē aʻe, ua hoʻoholo ʻia nā uku no ia mau mea. ʻO Farani wale nō, Kelemānia a me Switzerland ka uku no nā ʻano ʻokoʻa like ʻole. I Kelemānia a me Switzerland, ʻoi aku ka kiʻekiʻe o ke kumukūʻai o ke kaʻina ma o ke ala apical. Ke hoʻonui nei kēia kulekele hoʻihoʻi i ka nui o nā poʻe e loaʻa ana i ka papahana TAVR.
E noi i kahi laʻana o kēia hōʻike noiʻi@ https://www.gminsights.com/request-sample/detail/3170
ʻO ka ulu nui ʻana o nā mea hana i nā ʻāina e kū mai ana e like me ka Middle East a me ʻApelika e alakaʻi i ka hoʻonui ʻana o ka mākeke transcatheter heart valve replacement. ʻO ka nui o nā lāhui like ʻole ma ka Hikina Hikina a me ʻApelika i hoʻopilikia nui ʻia e ka maʻi cardiovascular. No laila, ke nānā aku nei nā mea hana haole i ka hoʻokō ʻana i ka koi a me ka hoʻolako ʻana i nā kīwaha puʻuwai transcatheter. ʻO ka maʻamau o ka stenosis valve aortic i ka Middle East ua hoʻonui i ka hoʻohana ʻana o ka transcatheter heart valve replacement surgery. No laila, ma ka Middle East a me ʻApelika, ʻike nā mea hana valve aortic i nā manawa ulu nui.
ʻO ka māhele o ka mākeke pani pani pani transcatheter i ʻoi aku ma mua o $ 537 miliona ma 2019. Hoʻohana nui ʻia ka hoʻololi ʻana o ka pulmonary valve transcatheter no ka mālama ʻana i ka leaky a i ʻole stenotic pulmonary valves a i ʻole nā mea maʻi me ka maʻi hiki ke hoʻopaʻa ʻia i nā kīwaha pulmonary surgically implanted. No ka laʻana, pono nā poʻe maʻi me nā ʻāʻī arterial a me nā mea maʻi me ka pulmonary atresia a i ʻole ke kāʻei Ross e hoʻololi i ke kīpē pulmonary transcatheter. Eia kekahi, ʻo ka transcatheter pulmonary valve e hoʻemi i ka helu o nā ʻoki puʻuwai e pono ai ka mea maʻi e hana i ko lākou ola. Hāʻawi pū kēia mea i ka noi no nā kīwaha pulmonary transcatheter.
ʻO ke ala transapical i loko o ka mākeke pani pani puʻuwai transcatheter ua ʻoi aku ma mua o US $ 1.16 biliona ma 2019. ʻO ke ala transapical ke ala i makemake ʻia no ka mea hiki i ka mea hoʻohana ke kokoke i ka valve hiki ke hele maʻalahi i ka valve kūlohelohe me ka ʻōnaehana lawe. Hiki i kēia ʻano hana ke pale i ka ʻōnaehana hāʻawi mai ka hele ʻana a puni ka ʻaoʻao aortic, a laila e hōʻemi i ka hopena o ka hahau ʻana i ka transcatheter aortic valve replacement. Eia kekahi, ʻo ka transapical approach ke ʻano o ke koho ʻana no ka hapa nui o nā mea mālama olakino no ka mea hāʻawi ia i ka haʻahaʻa haʻahaʻa o nā hoʻopiʻi e pili ana i ke ala. Hiki i kēia mau mea ke alakaʻi i ka noi no nā kīwaha puʻuwai transcatheter.
Ma muli o ke ao holoʻokoʻa o ka mitral regurgitation a me ka mitral valve stenosis, ka transcatheter heart valve replacement market no ka mitral valve heart disease applications e hōʻike i kahi ulu ulu o ka ʻoi aku o 23.1% e 2026. Wahi a nā ʻatikala i paʻi ʻia, ʻoi aku ma mua o 4 miliona mau kānaka ma ka Ua pilikia ʻo ʻAmelika Hui Pū ʻIa i ka mitral regurgitation, a ʻo ka helu makahiki ma kahi o 50,000. Manaʻo ʻia nā poʻe maʻi me kēia maʻi e hoʻololi i ka transcatheter mitral valve. No laila, ke piʻi wikiwiki nei ka noi no nā puʻuwai transcatheter. Ke hoʻāʻo nei nā mea hoʻololi i ka transcatheter mitral valve, kahi e hoʻonui ai i ka nui o nā maʻi e hoʻololi ana i ka transcatheter mitral valve.
Ua manaʻo ʻia e 2026, e ulu ana ka māhele o ka haukapila i ka mākeke transcatheter heart valve replacement ma kahi CAGR o 14.1%. E loaʻa i nā halemaʻi nā uku hoihoi, e koi ana i nā poʻe maʻi ma waena o nā keʻena lapaʻau ʻē aʻe e koho i nā halemai no ka hoʻololi ʻana i ka puʻuwai transcatheter ma muli o ke kumukūʻai kiʻekiʻe o kēia mau hana. Eia kekahi, ʻo ka hoʻonui ʻana o ke aupuni i ka hoʻokele ʻana i nā maʻi valve kekahi kumu i ka hoʻonui ʻana i ka ʻoihana haukapila.
Ua lanakila ʻo Brazil i ka mākeke transcatheter heart valve replacement market ma Latin America. Ke alakaʻi ʻia e ka ulu ʻana o ka poʻe ʻelemakule e loaʻa ana i ka maʻi aortic valve, ʻo Brazil i helu ʻia he US $ 47 miliona ma 2019. I nā makahiki i hala iho nei, ua piʻi nui ka nui o nā maʻi me ka maʻi aortic calcified non-rheumatic ma Brazil. No laila, i nā makahiki i hala iho nei, ua hoʻonui ʻia ka ʻae ʻana o ka home o ka transcatheter heart valve replacement technology, ka mea i alakaʻi i ka hoʻonui ʻana i ka noi a me ka hāʻawi ʻana i nā kīwaha naʻau transcatheter. ʻO ka piʻi wikiwiki ʻana o ka nui o nā halemai ma ka ʻāina a me ka ikaika o nā mea pāʻani ʻoihana kaulana e hoʻopukapuka nei i ka hoʻomohala ʻana o nā puʻuwai transcatheter hou i hoʻolaha hou i ka noi mākeke.
ʻO kekahi o nā hui nui e hana ana i ka mākeke transcatheter heart valve replacement market me 4C Medical Technologies, Abbott, Boston Scientific, Edwards Lifesciences, HighLife Medical, JC Medical, LivaNova, Medtronic plc a me Neovasc. Ua hoʻomau mau ka poʻe komo i ka ʻoihana i ka hoʻokuʻu ʻana i nā huahana hou e hoʻonui i ko lākou wahi ʻāina a me ka waihona mea kūʻai.
ʻO Global Market Insights, Inc., i hoʻokumu ʻia ma Delaware, he noiʻi mākeke honua a me ka lawelawe kūkākūkā, e hāʻawi ana i nā hōʻike noiʻi syndicated a maʻamau a me nā lawelawe kūkākūkā ulu. Hāʻawi kā mākou ʻoihana naʻauao a me ka noiʻi noiʻi ʻoihana i nā mea kūʻai aku i nā ʻike ʻike a me ka ʻikepili mākeke kūpono, i hoʻolālā kūikawā ʻia a hōʻike ʻia e kōkua i nā hoʻoholo hoʻoholo. Hoʻolālā ʻia kēia mau hōʻike kikoʻī ma o nā ʻano noiʻi proprietary a hiki ke hoʻohana ʻia i nā ʻoihana koʻikoʻi e like me ke kemika, nā mea holomua, ka ʻenehana, ka ikehu hou a me ka biotechnology.
Arun Hegde (Arun Hegde) ʻAmelika Hui Pū ʻIa Kūʻai Global Market Insights Company Phone: 1-302-846-7766 Toll Free: 1-888-689-0688 Email: [Email protected]
transcatheter-heart-valve.png Ma ka makahiki 2026, ua manaʻo ʻia ka ulu ʻana o ka mākeke transcatheter heart valve replacement he 17.6%: GMI: ʻO nā mea pāʻani mākeke nui i ka transcatheter heart valve replacement me 4C Medical Technologies, Abbott, Boston Scientific, Edwards Life ʻEpekema, HighLife Medical, JC Medical, LivaNova, Medtronic plc.
Ka manawa hoʻouna: Jan-19-2021
